Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation

Liver Transplantation

Volumn 20, Issue 2, 2014, Pages 200-209

  Salah, Adeeb ^a   Fujimoto, Masakazu ^a   Yoshizawa, Atsushi ^a   Yurugi, Kimiko ^a   Miyagawa Hayashino, Aya ^a   Sumiyoshi, Shinji ^a   Minamiguchi, Sachiko ^a   Uemoto, Shinji ^a   Maekawa, Taira ^a   Haga, Hironori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; HLA DR ANTIGEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT ATRESIA; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; FLUORESCENCE; GRAFT DYSFUNCTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; STEROID THERAPY;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; ALLOGRAFTS; ANTIBODIES; BIOPSY; BLOOD GROUP INCOMPATIBILITY; CHILD; CHILD, PRESCHOOL; COMPLEMENT C4B; FEMALE; FIBROSIS; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; INFANT; ISOANTIBODIES; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84893155990     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23789     Document Type: Article

References (28)

1. Sakashita H, Haga H, Ashihara E, Wen MC, Tsuji H, Miyagawa-Hayashino A, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684.
2. Haga H, Egawa H, Fujimoto Y, Ueda M, Miyagawa-Hayashino A, Sakurai T, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: 457-464.
3. Ali S, Ormsby A, Shah V, Segovia MC, Kantz KL, Skorupski S, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol 2012; 26: 62-69.
4. Lunz J, Ruppert KM, Cajaiba MM, Isse K, Bentlejewski CA, Minervini M, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171-182.
5. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
6. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
7. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
8. Hübscher SG,. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012; 17: 280-286.
9. Colvin RB, Smith RN,. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
10. Michaels PJ, Fishbein MC, Colvin RB,. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25: 119-140.
11. Böhmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.
12. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ,. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749.
13. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
14. Schmeding M, Dankof A, Krenn V, Krukemeyer MG, Koch M, Spinelli A, et al. C4d in acute rejection after liver transplantation-a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523-530.
15. Bellamy CO,. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls. Liver Transpl 2011; 17: 747-750.
16. Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628-639.
17. Wallace WD, Reed EF, Ross D, Lassman CR, Fishbein MC,. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant 2005; 24: 1565-1570.
18. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449-454.
19. Raut V, Mori A, Kaido T, Ogura Y, Taku I, Nagai K, et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012; 93: 99-105.
20. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
21. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31: 792-799.
22. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
23. Haga H, Egawa H, Shirase T, Miyagawa A, Sakurai T, Minamiguchi S, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 16-27.
24. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
25. Hori T, Uemoto S, Takada Y, Oike F, Ogura Y, Ogawa K, et al. Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Surgery 2010; 147: 840-844.
26. Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840.
27. Gordon RD, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715.
28. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.